Flashpoint Therapeutics, a clinical-stage biotechnology company developing precision-engineered structural nanomedicines, appointed Barry Labinger as Chief Executive Officer.  Labinger joins Flashpoint at a time when the company aims to advance its scientific platform toward key clinical milestones. With over three decades of executive experience in the biopharmaceutical industry, Labinger brings a track record of building and leading innovative life sciences organizations through critical...